Cancer‐associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. Issue 4 (7th June 2022)

• Record Type: Journal Article
• Authors: Menezes, Shinelle; Okail, Mohamed Hazem; Jalil, Siti Munira Abd; Kocher, Hemant M; Cameron, Angus J M
• Is Part Of: Journal of pathology. Volume 257:Issue 4(2022)
• Page Start: 526
• Page End: 544
• Publication Date: 2022-06-07
• Subjects: cancer‐associated fibroblasts -- immunotherapy -- in vivo models -- knock‐out models -- myofibroblast -- pancreatic cancer; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5926
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Cancer‐associated fibroblasts (CAFs) have conflicting roles in the suppression and promotion of cancer. Current research focuses on targeting the undesirable properties of CAFs, while attempting to maintain tumour‐suppressive roles. CAFs have been widely associated with primary or secondary therapeutic resistance, and strategies to modify CAF function have therefore largely focussed on their combination with existing therapies. Despite significant progress in preclinical studies, clinical translation of CAF targeted therapies has achieved limited success. Here we will review our emerging understanding of heterogeneous CAF populations in tumour biology and use examples from pancreatic ductal adenocarcinoma to explore why successful clinical targeting of protumourigenic CAF functions remains elusive. Single‐cell technologies have allowed the identification of CAF subtypes with a differential impact on prognosis and response to therapy, but currently without clear consensus. Identification and pharmacological targeting of CAF subtypes associated with immunotherapy response offers new hope to expand clinical options for pancreatic cancer. Various CAF subtype markers may represent biomarkers for patient stratification, to obtain enhanced response with existing and emerging combinatorial therapeutic strategies. Thus, CAF subtyping is the next frontier in understanding and exploiting the tumour microenvironment for therapeutic benefit. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.